Profile

Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating conditions with limited treatment options and high mortality. Backed by a team with a proven track record, including the design of an antibody that led to a $1.2B acquisition deal in 2021, Paradox uses a proprietary platform that requires only the native protein structure to develop antibodies that selectively deplete pathological proteins and currently has three new candidates ready to disrupt the protein misfolding industry.

Event details

Date: January 12 - 14, 2026

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total
  • 20/20 OptimEyes Technologies Inc.
    20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
  • BioBox
    BioBox is a data integration and decision-intelligence platform for drug discovery. It helps biopharma bring…
  • Eurofins CDMO Alphora Inc.
    Eurofins CDMO Alphora develops and…
  • Fibra
    Fibra turns everyday underwear into a real-time reproductive health platform — capturing critical biomarker data…
  • GL Chemtec International Ltd.
    For over two decades, Toronto area-based GL CHEMTEC has been dedicated to delivering innovative…
  • HDAX Therapeutics
    HDAX Therapeutics, a biotechnology company pioneering a novel approach to target…
  • ImmunoBiochem Corporation
    ImmunoBiochem is a pharma-partnered biotech developing novel bioconjugate therapeutics, such as…
  • Iseehear Inc.
    Iseehear Inc. is a leading provider of comprehensive IT solutions for…
  • Kapoose Creek Bio
    Kapoose Creek Bio is pioneering a new generation of therapeutics by fusing nature’s untapped chemistry with…
  • Lumerate
    Lumerate is launching a new software brand called BioBackers - the intelligence platform for life science…
  • Medicenna Therapeutics
    Medicenna is a clinical-stage immunotherapy company pioneering best- and/or first-in-class Superkines -…
  • Noa Therapeutics
    Noa Therapeutics has developed a proprietary NRF2-…
  • Nucro-Technics
    Nucro-Technics is a GLP- and…
  • Paradox Immunotherapeutics
    Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating…
  • Pattern Pharma Inc.
    Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. PQ…
  • QurCan Therapeutics Inc.
    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS…
  • Rhythm Biotherapeutics Inc.
    Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation…
  • Spiderwort Biotechnologies Inc.
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • Tenomix
    Tenomix’s mission is to develop novel technologies that target inefficiencies in the pathology workflow, optimize…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…